Goldman Sachs
GS
$865.82
-0.36%
Goldman Sachs is a global investment bank operating across investment banking (M&A advisory, equity and debt underwriting), global markets (equities and FICC sales and trading), asset and wealth management, and a small, shrinking platform solutions/consumer lending book, with roughly 30% of post-provision revenue now coming from more predictable fee-based asset and wealth management. The firm is the undisputed leader in M&A advisory by revenue for two decades running, giving it a franchise identity as the premier bulge-bracket advisor to corporates, sponsors, and governments rather than a balance-sheet-driven commercial bank. The current investor debate centers on whether the powerful capital-markets upcycle — evidenced by a 72% surge in equities revenues and a strong Q3 beat on investment banking — can be sustained, and on management's strategic push into ETFs via the up-to-$2.25 billion acquisition of NEOS Investments to deepen its asset-management mix. Against that, the stock has de-rated sharply since mid-summer as investors question peak-cycle earnings, trading-related volatility, and whether the fee-based diversification is enough to offset the cyclicality of trading and advisory revenue.…
GS
Goldman Sachs
$865.82
Related headlines
Investment Opinion: Should I buy GS Today?
Rating: Hold, with a catalyst-driven bias toward accumulating on confirmation. The core thesis is that Goldman Sachs is a premier capital-markets franchise trading at a discounted 12.07x forward earnings and 2.20x book after a 22% de-rating from its July high, but the 21-analyst consensus (9 Buy, 15 Hold, 2 Sell, mean score 2.46) and the $1,030.67 average target (+15.0% upside) both signal that the market wants proof of trading-revenue durability before paying up. The stock is cheap for a reason — the debate is peak-cycle earnings, not franchise quality.
The supporting evidence is genuinely constructive: revenue grew 17.25% year-over-year to $37.70 billion in Q3 2026, net margin expanded to 14.04% from 12.74% and gross margin to 48.57% from 46.17%, and the PEG of 0.65 sits well below 1.0. The 13.74% ROE and leading M&A advisory franchise justify the premium to diversified banks (low-to-mid teens PE, 1.0-1.5x P/B), while the 12.07x forward multiple versus 16.92x trailing implies the market already discounts an earnings peak — consensus 2027 EPS of $84.15 versus the $76.33 low estimate brackets the risk. The 1.92% dividend yield and $859 million of Q3 buybacks provide modest support, though trailing FCF of -$75.21 billion means capital return relies on balance-sheet capacity, not internal cash generation.
The biggest risks that could invalidate the thesis are a trading-revenue rollover (Q3 EPS of $17.01 already fell from Q2's $20.98), a break below the $875-$878 October support that opens the door to the $754 52-week low, and multiple compression from 2.20x P/B near the top of its 0.93x-2.47x historical band. This Hold would upgrade to Buy if Q4 confirms trading-revenue durability and the stock reclaims the $925-$950 resistance shelf, or downgrade to Sell if revenue growth decelerates below 10% or forward EPS estimates drift toward the $76.33 low. Verdict: fairly valued to modestly undervalued on forward earnings, but expensive on book value — a stock to own patiently, not to chase.
Sign up to view all
GS 12-Month Price Forecast
Goldman Sachs presents a genuinely two-sided setup: the fundamentals are improving (17.25% revenue growth, expanding margins, 13.74% ROE) and the valuation is undemanding at 12.07x forward earnings with a 0.65 PEG, yet the stock is in a confirmed downtrend and the analyst community is functionally on hold. The 15% implied upside to the $1,030.67 mean target is respectable but not compelling enough to override a 71% target spread that quantifies how uncertain the forward earnings base really is. The single variable that resolves the debate is whether Q4 confirms the 72% equities revenue surge as a durable upcycle or exposes it as peak-cycle earnings — everything else, including the NEOS ETF deal, is secondary to that question. I would upgrade to bullish if the stock reclaims the $925-$950 resistance shelf on a Q4 beat with trading revenue holding, and downgrade to bearish if it breaks below $875 or forward EPS estimates drift toward the $76.33 low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Goldman Sachs's 12-month outlook, with a consensus price target around $1030.67 and implied upside of +19.0% versus the current price.
Average Target
$1030.67
26 analysts
Implied Upside
+19.0%
vs. current price
Analyst Count
26
covering this stock
Price Range
$730 - $1250
Analyst target range
Coverage is broad with 21 analysts, but sentiment is tepid: 9 Buy, 15 Hold, and 2 Sell, yielding a consensus recommendation of "buy" on a mean score of 2.46 (where 1 is strong buy and 5 is strong sell) — effectively a hold-biased consensus despite the label. The average target price of $1,030.67 implies +15.0% upside from the current $896.09, a respectable but not aggressive call that reflects the stock's 22% decline from its July high; the consensus is best characterized as cautiously constructive, with the majority of analysts unwilling to pound the table after the de-rating. The target range is wide — $730 low to $1,250 high, a 71% spread — signaling genuine disagreement about the cycle: the high target assumes multiple expansion back toward prior peaks on sustained capital-markets strength and successful ETF/asset-management integration (NEOS), while the low target of $730 (below the 52-week low of $754) prices in a sharp trading-revenue downturn and margin compression. Recent institutional actions skew neutral-to-mildly positive — Freedom Broker upgraded to Buy from Hold on October 23, Evercore ISI maintains Outperform, but UBS, JPMorgan, Citigroup, RBC, BMO, and KBW all reiterated Neutral/Market Perform/Sector Perform in mid-October — a pattern of analysts holding fire until they see whether Q4 confirms the trading-revenue durability; the wide spread and heavy neutral cluster argue for position sizing discipline and a catalyst-driven entry rather than a momentum chase.
Drowning in data?
Find the real signal!
Bulls vs Bears: GS Investment Factors
The bear case currently has stronger near-term evidence: the stock is in a confirmed downtrend (-15.49% over three months, -23.99% max drawdown), the analyst consensus is functionally a hold (2.46 mean, 15 of 21 at Hold), and relative strength has collapsed by 13.48 points versus SPY over three months. The bull case rests on valuation and fundamentals — 12.07x forward PE, 17.25% revenue growth, expanding margins, and a 15% implied upside to the $1,030.67 mean target — which are real but have not yet arrested the de-rating. The single most important tension is whether the Q3 capital-markets surge (72% equities revenue growth) is a durable upcycle or peak-cycle earnings; if Q4 confirms trading-revenue durability, the 12x forward multiple re-rates sharply higher, but if trading revenues roll over, the low target of $730 (below the 52-week low) becomes the reference point. Until that question is answered by the next print, the evidence favors patience over accumulation.
Bullish
- Forward PE of 12.07x discounts a peak: At $896.09 the stock trades at 16.92x trailing but only 12.07x forward earnings, with consensus 2027 EPS of $84.15 versus the trailing run-rate. That gap means the market is already pricing a cyclical earnings peak rather than paying up for growth, leaving limited multiple downside if earnings merely hold.
- Revenue up 17.25% YoY with margin expansion: Q3 2026 revenue of $37.70 billion rose 17.25% from $32.15 billion a year earlier, while net margin expanded to 14.04% from 12.74% and gross margin to 48.57% from 46.17%. The improvement is structural across the P&L, not just a revenue headline.
- Analyst average target implies 15% upside: The $1,030.67 mean target across 21 analysts represents +15.0% upside from $896.09, with a high target of $1,250 implying +39.5%. Even the low target of $730 is only -18.5% below spot, giving an asymmetric risk/reward skew at current levels.
- PEG of 0.65 signals growth-adjusted value: A PEG ratio of 0.65 — well below 1.0 — indicates the stock is cheap relative to its earnings growth rate, and the 2.20x P/B sits below the 2.47x peak reached in Q2 2026. For a franchise with 13.74% ROE and the leading M&A advisory position, that is an undemanding multiple.
Bearish
- Broken uptrend, -23.99% max drawdown: The stock is down 15.49% over three months and sits at just 35.6% of its 52-week range ($754.00-$1,153.99), having fallen 22% from its July high near $1,152. The -23.99% max drawdown confirms a genuine trend break, not a shallow pullback.
- Consensus is hold-biased despite 'buy' label: Of 21 analysts, 15 rate Hold and only 9 Buy (with 2 Sell), producing a recommendation mean of 2.46 — effectively a hold. Six major houses (UBS, JPMorgan, Citigroup, RBC, BMO, KBW) all reiterated Neutral in mid-October, signaling unwillingness to underwrite the cycle.
- Negative $75.21 billion trailing free cash flow: Trailing FCF is -$75.21 billion, driven by Q3 operating cash flow of -$31.15 billion from trading-book working capital. With debt-to-equity at 4.88x and a current ratio of 0.83, capital return ($859 million of Q3 buybacks plus dividends) depends on balance-sheet capacity rather than internal cash generation.
- Relative strength collapse vs. SPY: GS outperformed SPY by 3.69 points over one year but lagged by 13.48 points over three months and 12.62 points YTD. That rotation out of capital-markets beta, combined with a 1.272 beta, means a 10% SPY decline historically implies roughly a 13% GS decline.
GS Technical Analysis
Goldman Sachs is in a clear medium-term downtrend despite a positive one-year return of +14.08%, with the stock now at $896.09 versus a 52-week high of $1,153.99 and a 52-week low of $754.00 — placing it at roughly 35.6% of its 52-week range, deep in the lower half. That positioning signals a broken uptrend and a market that has already priced in substantial bad news, rather than a stock riding momentum near highs; the -23.99% max drawdown confirms a meaningful correction from the July peak near $1,152. The recent momentum is decisively negative: the stock is down -15.49% over three months and -0.72% over one month, while the one-year figure remains +14.08%, a classic divergence where the long-term trend is being unwound by a sharp short-term reversal. Relative strength tells the story — GS outperformed SPY by +3.69 points over one year but lagged by -13.48 points over three months and -12.62 points YTD, indicating institutional rotation out of capital-markets beta; the modest -0.29% single-day move on 1.44 million shares suggests selling is orderly rather than panic-driven. Key support sits at the $875-$878 zone (recent October lows) and then the $754 52-week low, while resistance is layered at $925-$950 (the broken September support shelf) and ultimately $1,153.99; a reclaim of $950 would signal trend repair, whereas a break below $875 opens the door to a retest of the $754 low. With a beta of 1.272, GS is roughly 27% more volatile than the market, so position sizing should account for amplified drawdowns in risk-off regimes — a 10% SPY decline historically implies a ~13% GS decline.
Beta
1.27
1.27x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$754-$1154
Price range past year
Annual Return
+9.9%
Cumulative gain past year
| Period | GS Return | S&P 500 |
|---|---|---|
| 1m | -2.4% | -5.4% |
| 3m | -16.7% | -4.9% |
| 6m | -7.5% | -0.3% |
| 1y | +9.9% | +9.7% |
| ytd | -5.3% | +7.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GS Fundamental Analysis
Revenue is growing robustly: Q3 2026 revenue of $37.70 billion rose 17.25% year-over-year versus $32.15 billion in Q3 2025, and the trailing four quarters total roughly $123.5 billion ($30.1B + $17.2B + $38.4B + $37.7B), with the sequential pattern showing Q1's $17.23 billion (a seasonally light quarter), Q2's $38.43 billion, and Q3's $37.70 billion — a trajectory that reflects a powerful capital-markets recovery rather than deceleration. Segment data show Global Markets at $13.46 billion and Investment Management at $5.05 billion driving the mix, with Platform Solutions a negligible $170 million, confirming that trading and asset management — not consumer — are the growth engines, consistent with the 72% equities revenue surge cited in Q3 coverage. Profitability is strong and improving: Q3 net income was $5.29 billion on a 48.57% gross margin and 14.04% net margin, with diluted EPS of $17.01, while Q2 delivered $6.63 billion of net income at a 52.66% gross margin and $20.98 diluted EPS — the sequential dip reflects seasonally lower Q3 trading, not structural margin compression, and the 17.47% operating margin remains healthy for a capital-markets franchise. Balance-sheet leverage is the key risk: debt-to-equity stands at 4.88x with a current ratio of 0.83, and trailing free cash flow is deeply negative at -$75.21 billion, driven by working-capital swings in the trading book (Q3 operating cash flow of -$31.15 billion) rather than operating losses — ROE of 13.74% and ROA of 1.11% are respectable but below the firm's through-cycle targets, and the negative FCF means capital return ($859 million of Q3 buybacks plus dividends) is funded from earnings and balance-sheet capacity rather than internal cash generation, which is normal for a broker-dealer but limits financial flexibility if markets seize up.
Quarterly Revenue
$37.7B
2026-09
Revenue YoY Growth
+17.3%
YoY Comparison
Gross Margin
48.6%
Latest Quarter
Free Cash Flow
$-40.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GS Overvalued?
Because Goldman Sachs is solidly profitable (Q3 net income of $5.29 billion, positive trailing EPS), the PE ratio is the appropriate primary metric: the stock trades at 16.92x trailing earnings and just 12.07x forward earnings, and the wide gap between trailing and forward multiples implies the market expects meaningful EPS growth — consensus 2027 EPS of $84.15 versus a trailing run-rate that supports the lower trailing multiple. On a price-to-book basis the stock trades at 2.20x, and its PEG of 0.65 suggests the growth-adjusted valuation is undemanding, while the 2.20x PS and 1.55x EV/Sales are less informative for a balance-sheet-heavy bank. Relative to the capital-markets peer group, GS's 16.9x trailing PE and 2.2x P/B sit at a premium to the diversified-bank average (typically low-to-mid teens PE and 1.0-1.5x P/B), a premium justified by its leading M&A franchise, higher ROE (13.74%), and superior growth (17.25% revenue growth) — but the 12.07x forward PE implies the market is already discounting a cyclical earnings peak rather than paying up for it. Historically, GS's PE has ranged from roughly 8.9x (Q1 2024) to 25.8x (Q2 2023) and its P/B from 0.93x (Q3 2023) to 2.47x (Q2 2026); at 2.20x P/B the stock sits near the top of its own book-value band, suggesting the market is pricing in optimistic franchise value, while the 16.9x PE is mid-range — a mixed signal that argues for patience rather than chasing, with the 1.92% dividend yield offering modest support.
PE
16.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~18x
vs. Industry Avg
21.7x
Industry PE ~21.7x*
EV/EBITDA
30.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the balance sheet and earnings quality. Debt-to-equity of 4.88x and a current ratio of 0.83 leave limited liquidity cushion, while trailing free cash flow of -$75.21 billion (Q3 operating cash flow -$31.15 billion) reflects trading-book working-capital swings that can turn violently in a risk-off tape. Earnings are highly concentrated in cyclical engines — Global Markets at $13.46 billion and Investment Management at $5.05 billion drove the Q3 mix, with Platform Solutions a negligible $170 million — so a trading slowdown hits revenue directly, as shown by the EPS drop from $20.98 in Q2 to $17.01 in Q3. ROE of 13.74% and ROA of 1.11% remain below through-cycle targets, meaning any margin compression has an outsized effect on book-value compounding.
Market and competitive risks are dominated by valuation and cyclicality. At 2.20x P/B the stock sits near the top of its historical 0.93x-2.47x band, so multiple compression alone could erase a year of earnings growth; the 16.92x trailing PE is mid-range but the 12.07x forward multiple assumes consensus EPS of $84.15 materializes. Beta of 1.272 amplifies drawdowns — a 10% SPY decline historically implies roughly a 13% GS decline — and the 13.48-point three-month relative-strength lag versus SPY shows institutional rotation out of capital-markets beta is already underway. The NEOS ETF acquisition (up to $2.25 billion for a $30 billion ETF business) is strategically sound but adds integration risk and will not meaningfully move earnings near term, while competitive pressure in M&A advisory and trading from bulge-bracket peers and electronic market makers persists.
The worst-case scenario is a capital-markets downturn that simultaneously compresses trading revenue, stalls M&A advisory, and forces multiple contraction. In that chain, forward EPS estimates of $84.15 get cut toward the $76.33 low estimate, and the multiple de-rates toward the 8.9x trough seen in Q1 2024 — a combination that supports the $730 analyst low target, which sits below the $754 52-week low. From the current $896.09, that represents roughly -18.5% downside to the low target and about -15.9% to the 52-week low, with a retest of the $875-$878 October support zone as the first trigger and a break below $875 opening the door to the $754 level. A full replay of the -23.99% max drawdown from the July high would imply a price near $876, consistent with the lower end of the bear range.
FAQ
Ranked by severity, the first is earnings cyclicality: EPS fell from $20.98 in Q2 to $17.01 in Q3 as trading normalized, and a sustained rollover would push forward estimates toward the $76.33 low, which combined with multiple compression supports the $730 bear target. Second is balance-sheet and liquidity risk: debt-to-equity of 4.88x, a current ratio of 0.83, and trailing free cash flow of -$75.21 billion (Q3 operating cash flow -$31.15 billion) mean capital return depends on balance-sheet capacity rather than internal cash generation. Third is valuation compression: at 2.20x P/B near the top of its 0.93x-2.47x band, de-rating alone could erase a year of earnings growth. Fourth is macro and market beta: at 1.272, a 10% SPY decline historically implies roughly a 13% GS decline, and the stock has already lagged SPY by 13.48 points over three months as institutions rotate out of capital-markets beta.
The 12-month view splits into three scenarios. The base case (50% probability) targets $1,000-$1,060, assuming consensus 2027 EPS of $84.15 broadly materializes, Global Markets holds within 10% of the Q3 run-rate, and the forward multiple stays at 12x-14x as peak-cycle risk is debated. The bull case (25%) targets $1,150-$1,250, requiring a durable capital-markets upcycle, a Q4 confirmation of the 72% equities surge, M&A backlog conversion including the Anthropic IPO, and a re-rating toward the 2.47x P/B peak. The bear case (25%) targets $730-$800, driven by a trading-revenue rollover, EPS cuts toward $76.33, and de-rating toward the 8.9x trough. The base case is most likely, and its key assumption is that trading revenue normalizes rather than collapses — the one variable that most changes the outcome.
The answer depends on the metric, and that split is the heart of the debate. On earnings the stock looks modestly undervalued: 16.92x trailing but only 12.07x forward, with a 0.65 PEG and consensus 2027 EPS of $84.15 — the wide trailing-to-forward gap means the market is already discounting a cyclical peak rather than paying for growth. On book it looks closer to expensive: 2.20x P/B sits near the top of the historical 0.93x-2.47x band, well above the 1.0-1.5x typical of diversified banks, a premium justified by the leading M&A franchise, 13.74% ROE, and 17.25% revenue growth. The 2.20x PS and 1.55x EV/Sales are less informative for a balance-sheet-heavy broker-dealer. Net, the market is pricing a fair-to-slightly-cheap earnings multiple alongside an optimistic franchise-value premium — implying it expects earnings to hold but is unwilling to pay peak-cycle multiples until a full cycle is proven.
On risk/reward, the setup is balanced rather than compelling: the $1,030.67 mean analyst target implies +15.0% upside from $896.09, and even the $730 low target is only about -18.5% below spot, so the skew is mildly favorable. The valuation supports patience — 12.07x forward earnings, a 0.65 PEG, and 2.20x book below the 2.47x Q2 2026 peak — but the stock is in a confirmed downtrend (-15.49% over three months, -23.99% max drawdown) and 15 of 21 analysts rate it Hold with a 2.46 mean score. The biggest downside risk is a trading-revenue rollover that cuts forward EPS toward the $76.33 low while the multiple de-rates toward the 8.9x Q1 2024 trough. It is a reasonable buy for a patient investor with a 12-24 month horizon who accumulates on confirmation — a Q4 beat with trading revenue holding and a reclaim of $925-$950 — rather than chasing here; for a short-term trader, the broken trend argues against entry before that confirmation.
The profile favors medium-to-long-term holding over short-term trading. The 1.272 beta, quarterly EPS swings from $17.01 to $20.98, and a -23.99% max drawdown make short-term price action dominated by trading-book seasonality and market beta rather than franchise value, offering poor risk-adjusted odds for momentum traders in a confirmed downtrend. For longer horizons, the 13.74% ROE, 17.25% revenue growth, leading M&A franchise, and 1.92% dividend with a conservative 0.31 payout ratio support compounding, and the 12.07x forward multiple limits valuation downside if earnings merely hold. Earnings visibility is moderate — consensus 2027 EPS of $84.15 versus a $76.33-$87.69 range is a 15% spread — so a minimum holding period of 12-24 months is appropriate to ride through at least one full trading cycle and let the peak-cycle question resolve.